Barclays PLC Increases Position in Zura Bio Limited (NASDAQ:ZURA)

Jan 6, 2025 · Barclays PLC raised its position in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 777.1% during the third quarter, according to the company in its most recent …

1%
OFF

Barclays PLC Increases Position In Zura Bio Limited (NASDAQ:ZURA)

2 weeks from now

Jan 6, 2025 · Barclays PLC raised its position in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 777.1% during the third quarter, according to the company in its most recent …

etfdailynews.com

1%
OFF

Barclays PLC Raises Stock Holdings In Zura Bio Limited …

2 weeks from now

Jan 6, 2025 · Barclays PLC increased its position in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 777.1% in the third quarter, according to its most recent 13F filing with the …

defenseworld.net

1%
OFF

Zura Bio FY2025 EPS Forecast Boosted By Leerink Partnrs

2 weeks from now

Dec 13, 2024 · Barclays PLC boosted its position in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company's stock valued at $260,000 …

marketbeat.com

$3.00
OFF

Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth In Short ...

2 weeks from now

Nov 29, 2024 · Shares of NASDAQ ZURA opened at $3.00 on Friday. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35. The firm has a 50 day moving average price of …

etfdailynews.com

7%
OFF

ZURA News Today | Why Did Zura Bio Stock Go Down Today?

2 weeks from now

6 days ago · Great Point Partners LLC trimmed its position in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 29.7% during the third quarter, according to its most recent filing with the …

marketbeat.com

6%
OFF

Geode Capital Management LLC Buys 377,545 Shares Of Zura Bio …

2 weeks from now

Jan 7, 2025 · Geode Capital Management LLC raised its stake in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 70.6% during the third quarter, according to its most recent …

marketbeat.com

$264000
OFF

Barclays PLC Has $264,000 Stock Holdings In Rapport Therapeutics ...

2 weeks from now

Jan 6, 2025 · Barclays PLC Increases Position in Zura Bio Limited (NASDAQ:ZURA) You might be interested in: 1,018 Shares in Taiwan Semiconductor Manufacturing Company Limited …

etfdailynews.com

FAQs about Barclays PLC Increases Position in Zura Bio Limited (NASDAQ:ZURA) Coupon?

Does Barclays PLC own Zura Bio Limited?

Barclays PLC raised its position in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 777.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,061 shares of the company’s stock after purchasing an additional 56,757 shares during the quarter. ...

Where can I buy shares of Zura bio?

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zura Bio own? ...

What is the benchmark for Zura Bio Limited (Zura)?

Benchmark is S&P 500 Select to analyze similar companies using key performance metrics; select up to 4 stocks. ZURA does not have Company Insights Find the latest Zura Bio Limited (ZURA) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

Will Zura Bio Limited post -0.65 EPs?

As a group, analysts predict that Zura Bio Limited will post -0.65 EPS for the current year. (Free Report) Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. ...

What did Zura bio do in Q2 2024?

HENDERSON, Nev., August 13, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its second quarter 2024 financial results, and recent business highlights. ...

Are research firms weighing in on Zura bio?

A number of research firms have recently weighed in on ZURA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Leerink Partners initiated coverage on shares of Zura Bio in a research note on Monday, November 4th. ...